Edition:
United States

Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

115.66USD
12:45pm EDT
Change (% chg)

$-4.02 (-3.36%)
Prev Close
$119.68
Open
$118.90
Day's High
$118.90
Day's Low
$115.66
Volume
217,569
Avg. Vol
562,469
52-wk High
$149.17
52-wk Low
$102.21

Latest Key Developments (Source: Significant Developments)

Alexion Pharmaceuticals Q2 Non-GAAP Earnings Per Share $2.07
Thursday, 26 Jul 2018 06:30am EDT 

Alexion Pharmaceuticals Inc ::ALEXION REPORTS SECOND QUARTER 2018 RESULTS.Q2 NON-GAAP EARNINGS PER SHARE $2.07.Q2 GAAP LOSS PER SHARE $2.05.Q2 REVENUE $1.045 BILLION VERSUS I/B/E/S VIEW $977.7 MILLION.Q2 EARNINGS PER SHARE VIEW $1.70 -- THOMSON REUTERS I/B/E/S.UPDATED FULL YEAR 2018 GUIDANCE.SEES 2018 TOTAL REVENUES $3,980 MILLION TO $4,010 MILLION.SEES 2018 EARNINGS PER SHARE GAAP $1.25 TO $1.50.SEES 2018 EARNINGS PER SHARE NON-GAAP $7.00 TO $7.15.ALEXION EXPECTS TO INCUR ADDITIONAL RESTRUCTURING AND RELATED EXPENSES IN 2018 OF APPROXIMATELY $10 MILLION TO $60 MILLION.ALEXION PHARMACEUTICALS - MAY INCUR RESTRUCTURING EXPENSES THAT ARE MATERIALLY DIFFERENT FROM CURRENT ESTIMATE.FY2018 EARNINGS PER SHARE VIEW $7.03, REVENUE VIEW $4.00 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Alexion offer for Wilson Therapeutics accepted
Friday, 25 May 2018 01:05am EDT 

May 25 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION OFFER FOR WILSON THERAPEUTICS ACCEPTED.ITS OFFER FOR SHARES IN WILSON BEEN ACCEPTED BY SHAREHOLDERS REPRESENTING 97.7 PCT OF TOTAL OF SHARES AND VOTES IN WILSON.ACQUISITION HAS ALSO BEEN APPROVED BY RELEVANT REGULATORY AUTHORITIES.TO GIVE WILSON'S SHAREHOLDERS ADDITIONAL TIME TO ACCEPT OFFER, CO HAS EXTENDED ACCEPTANCE PERIOD UNTIL JUNE 8, 2018.TO INITIATE COMPULSORY REDEMPTION PROCEEDINGS REGARDING REMAINING SHARES IN WILSON AND PROMOTE DELISTING FROM NASDAQ STOCKHOLM.OFFER FOR WILSON THERAPEUTICS MADE THROUGH A WHOLLY OWNED SUBSIDIARY OF CO.  Full Article

Alexion To Acquire Wilson Therapeutics
Wednesday, 11 Apr 2018 01:57am EDT 

April 11 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION TO ACQUIRE WILSON THERAPEUTICS.SAYS ALEXION WILL ACQUIRE WILSON THERAPEUTICS THROUGH A TENDER OFFER.SAYS TOTAL EQUITY VALUE OF TRANSACTION AMOUNTS TO SEK 7,100 MILLION, OR APPROXIMATELY $855 MILLION.SAYS ALEXION INTENDS TO FINANCE ACQUISITION THROUGH CASH ON HAND..  Full Article

Abeona Therapeutics Appoints Carsten Thiel, Ph.D., As Chief Executive Officer
Monday, 2 Apr 2018 08:15am EDT 

April 2 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS APPOINTS CARSTEN THIEL, PH.D., AS CHIEF EXECUTIVE OFFICER.TIM MILLER CONTINUES AS PRESIDENT AND ASSUMES CHIEF SCIENTIFIC OFFICER ROLE.THIEL MOST RECENTLY SERVED AS EXECUTIVE VICE PRESIDENT AND CHIEF COMMERCIAL OFFICER OF ALEXION PHARMACEUTICALS, INC.  Full Article

Alexion Announces Positive Top-Line Results Showing Successful Phase 3 Clinical Study Of ALXN1210
Thursday, 15 Mar 2018 06:30am EDT 

March 15 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION ANNOUNCES POSITIVE TOP-LINE RESULTS SHOWING SUCCESSFUL PHASE 3 CLINICAL STUDY OF ALXN1210 IN COMPLEMENT INHIBITOR TREATMENT-NAÏVE PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH).ALEXION PHARMACEUTICALS INC - SAFETY PROFILE OF ALXN1210 CONSISTENT WITH THAT SEEN FOR SOLIRIS.ALEXION PHARMACEUTICALS INC - REGULATORY SUBMISSIONS PLANNED IN UNITED STATES, EUROPEAN UNION, AND JAPAN IN SECOND HALF OF 2018.ALEXION PHARMACEUTICALS INC - SAFETY PROFILE OF ALXN1210 CONSISTENT WITH THAT SEEN FOR SOLIRIS.ALEXION PHARMACEUTICALS INC - ‍ALXN1210 ACHIEVED NON-INFERIORITY TO SOLIRIS ON CO-PRIMARY ENDPOINTS OF TRANSFUSION AVOIDANCE.ALEXION PHARMACEUTICALS INC - ‍ALXN1210 ACHIEVED ALL FOUR KEY SECONDARY ENDPOINTS​.ALEXION PHARMACEUTICALS INC - ‍ALXN1210 WAS GENERALLY WELL TOLERATED WITH A SAFETY PROFILE THAT IS CONSISTENT WITH THAT SEEN FOR SOLIRIS​.ALEXION PHARMACEUTICALS - ALXN1210 ALSO ACHIEVED NON-INFERIORITY TO SOLIRIS ON CO-PRIMARY ENDPOINTS OF LACTATE DEHYDROGENASE NORMALIZATION.  Full Article

Alexion Pharma Q4 GAAP Earnings Per Share $0.13
Thursday, 8 Feb 2018 06:30am EST 

Feb 8 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS AND PROVIDES FINANCIAL GUIDANCE FOR 2018.Q4 NON-GAAP EARNINGS PER SHARE $1.48.Q4 GAAP EARNINGS PER SHARE $0.13.Q4 REVENUE ROSE 9.5 PERCENT TO $909.7 MILLION.SEES FY 2018 REVENUE $3.85 BILLION TO $3.95 BILLION.SEES 2018 GAAP EARNINGS PER SHARE‍​ $4.35 TO $4.75.SEES 2018 NON-GAAP EARNINGS PER SHARE $6.60 TO $6.80.ALEXION PHARMACEUTICALS - GAAP INCOME TAX EXPENSE FOR QUARTER INCLUDES $45.8 MILLION CHARGE RELATED TO U.S. TAX REFORM.SEES 2018 GAAP OPERATING MARGIN 31% TO 34%.SEES 2018 NON-GAAP OPERATING MARGIN 48% TO 49%.ALEXION SAYS 2018 GUIDANCE ASSUMES GAAP EFFECTIVE TAX RATE OF 15 - 17 PERCENT (INCLUSIVE OF CO'S PROVISIONAL ASSESSMENT OF U.S. TAX REFORM IMPACT).  Full Article

Alexion reports Q3 non-GAAP earnings per share of $1.44
Thursday, 26 Oct 2017 06:30am EDT 

Oct 26 (Reuters) - Alexion Pharmaceuticals Inc :Alexion reports third quarter 2017 results.Q3 non-GAAP earnings per share $1.44.Q3 GAAP earnings per share $0.35.Q3 revenue $859 million versus I/B/E/S view $864.5 million.Q3 earnings per share view $1.32 -- Thomson Reuters I/B/E/S.Alexion Pharmaceuticals Inc - ‍provides updated 2017 guidance​.Alexion Pharmaceuticals Inc sees ‍ 2017 total revenues $3,475 million to $3,525 million​.Alexion Pharmaceuticals Inc sees ‍ 2017 GAAP earnings per share $2.00 to $2.35​.Alexion Pharmaceuticals Inc sees ‍ 2017 non-GAAP earnings per share $5.50 to $5.65​.Alexion Pharmaceuticals Inc - ‍2017 guidance assumes Soliris revenue impact of $80 million to $90 million from ALXN1210, other clinical trial recruitments.Alexion Pharma - ‍plans to initiate Single, PK-based Phase 3 study of ALXN1210 delivered subcutaneously once/ week to support registration in PNH, aHUS​.FY2017 earnings per share view $5.60 -- Thomson Reuters I/B/E/S.FY2017 revenue view $3.52 billion -- Thomson Reuters I/B/E/S.  Full Article

Alexion Pharmaceuticals says U.S. FDA approves Soliris for treatment of patients with GMG
Monday, 23 Oct 2017 08:27pm EDT 

Oct 23 (Reuters) - Alexion Pharmaceuticals Inc ::FDA approves soliris® (eculizumab) for the treatment of patients with generalized myasthenia gravis (gmg).  Full Article

Canada's PMPRB hearing panel issues decision in Soliris case
Wednesday, 27 Sep 2017 06:12pm EDT 

Sept 27 (Reuters) - :Canada's Patented Medicine Prices Review Board hearing panel issues decision in Soliris case.Canada's PMPRB says panel found that the price of Soliris (Eculizumab) 10 mg/ml was and is excessive under sections 83 and 85 of the patent act.Canada's PMPRB says panel ordered Alexion to lower price of soliris in canada as of sept 20 to no higher than lowest price in 7 comparator countries.  Full Article

BRIEF-Alexion announces interim analysis from phase 3 open-label extension study of Soliris
Wednesday, 13 Sep 2017 06:00pm EDT 

Adds company name in headline:Interim analysis from phase 3 open-label extension study shows sustained benefits of Soliris (Eculizumab) treatment for patients with refractory generalized myasthenia gravis.Says safety profile of Soliris was consistent with that observed in REGAIN study.Says ‍study is ongoing and planned to continue until January 2019​.Says ‍new results show sustained benefits across MG-specific assessment scales through additional 52 weeks for patients who continued to get Soliris​.Says benefits for patients treated with Soliris in REGAIN through 26 weeks were maintained in extension study across all four assessment scales.Says ‍safety profile of Soliris was consistent with that observed in REGAIN study​.Says benefits for patients treated with Soliris in REGAIN through 26 weeks were maintained in extension study.  Full Article

BRIEF-Alexion Reports Q1 Results And Positive Topline Data From ALXN1210 Phase 3 PNH Switch Study

* ALEXION REPORTS FIRST QUARTER 2018 RESULTS AND POSITIVE TOPLINE DATA FROM ALXN1210 PHASE 3 PNH SWITCH STUDY